Page 2 - Janx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Janx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Janx Today - Breaking & Trending Today

Old Well Partners LLC Makes New Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)

Old Well Partners LLC bought a new position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 10,300 shares of the company’s stock, valued at approximately $104,000. Several other hedge funds and […] ....

Immunomodulator Tracir , William Blair , Charles Schwab Investment Management Inc , Northern Trust Corp , Janux Therapeutics Inc , Old Well Partners , Barclays Plc , Exchange Commission , Janux Therapeutics , Free Report , Trust Corp , Schwab Investment Management , Therapeutics Trading Down , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Visit Holdingschannel , Janux Therapeutics Daily , Nasdaq Janx , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Janux Therapeutics (NASDAQ:JANX) Earns "Outperform" Rating from William Blair

Janux Therapeutics (NASDAQ:JANX – Get Free Report)‘s stock had its “outperform” rating reissued by equities researchers at William Blair in a report issued on Tuesday, RTT News reports. JANX has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and issued a $35.00 target price on shares of Janux Therapeutics […] ....

United States , Immunomodulator Tracir , William Blair , Tower Research Capital , Charles Schwab Investment Management Inc , Janux Therapeutics Company Profile , Janux Therapeutics Inc , American International Group Inc , Janux Therapeutics , Get Free Report , Schwab Investment Management , Wisconsin Investment Board , International Group , Research Capital , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx , Reiterated Rating ,

Janux Therapeutics (NASDAQ:JANX) Price Target Increased to $53.00 by Analysts at Wedbush

Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its target price hoisted by Wedbush from $24.00 to $53.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would indicate a potential upside of 250.99% from the company’s current […] ....

Immunomodulator Tracir , Nisa Investment Advisors , Cerity Partners , Sg Americas Securities , Janux Therapeutics Company Profile , Unisuper Management Pty Ltd , Janux Therapeutics Inc , Janux Therapeutics , Get Free Report , Super Management Pty Ltd , Investment Advisors , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx , Boost Price Target ,

Janux Therapeutics (NASDAQ:JANX) PT Raised to $53.00 at Wedbush

Janux Therapeutics (NASDAQ:JANX – Get Free Report) had its price target hoisted by Wedbush from $24.00 to $53.00 in a report released on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s target price would suggest a potential upside of 250.99% from the company’s previous close. Separately, HC Wainwright reiterated […] ....

United States , Immunomodulator Tracir , Tower Research Capital , Janux Therapeutics Inc , Charles Schwab Investment Management Inc , Janux Therapeutics Company Profile , American International Group Inc , Janux Therapeutics , Get Free Report , Schwab Investment Management , Wisconsin Investment Board , International Group , Research Capital , Tumor Activatedt Cell Engager , Tumor Activated Immunomodulator , Janux Therapeutics Daily , Nasdaq Janx , Boost Price Target ,